Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3550951 | 0.81 | ALDH1A1 (0.44) | HSPB1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL3552977 | 0.79 | CARM1 (0.40) | MAPTMEN1KMT2ATRPV4 | |
| SCHEMBL9526847 | 0.77 | HSPB1 (0.51) | HSPB1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL15820188 | 0.76 | HSPB1 (0.80) | HSPB1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL4729747 | 0.72 | HSPB1 (0.64) | HSPB1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL31011697 | 0.72 | MEN1 (0.50) | HSPB1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL1583899 | 0.71 | HSPB1 (0.63) | HSPB1MAPTALDH1A1MAPK1HTT | |
| SCHEMBL22114132 | 0.71 | HSPB1 (0.63) | HSPB1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL30545048 | 0.71 | HSPB1 (0.50) | HSPB1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL2644891 | 0.71 | LMNA (0.62) | HSPB1MAPTALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1935890-B1 | 2-HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE | MSD KK (JP) | 2016-03-16 | — | — | EP | disclosed |
| US-7799820-B2 | 2-Heterocycle-substituted indole derivatives for treating diabetes and associated conditions | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-09-21 | — | — | US | disclosed |
| US-20090118304-A1 | 2-HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-1935890-A1 | 2-HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118304-A1 | 2-HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE | GCKR, GPR119, GCK | HSPB1 3120/4885MAPT 4525/4885ALDH1A1 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.